Pharmaceutical trademarks - navigating through the FDA's pilot program
Pharmaceutical trademark creation and clearance continues to be one of the most difficult and challenging areas of trademark law.
The Food and Drug Administration (FDA) recently initiated a 2-year Pilot Program under PDUFA IV. The intent of the program is to enable participating pharmaceutical firms to evaluate proposed pharmaceutical marks and submit the data generated from those evaluations to the FDA for review.
Submitting a trademark to the FDA warrants questions: What supporting data is needed and accepted when proposing a mark? What issues might arise, and how can they be averted?
Join Thomson CompuMark for an on-demand pharmaceutical trademark webinar featuring industry leaders Robert E. Lee, Jr. (Assistant General Patent Counsel, Patents, Trademarks and Copyright for Eli Lilly and Company), James Thomas (Partner with Troutman Sanders LLP), and Maury M. Tepper III (Tepper & Eyster, PLLC) as they review the FDA pilot program, outline the requirements for submission and discuss what the changes will mean in clearing new pharmaceutical marks. They also present various approaches to trademark development and evaluation in light of the FDA’s views.
Additional information
Was this article useful?
Register now to receive KnowledgeLink direct to your mailbox every two months.
Download a PDF of all
February 2010's
KnowledgeLink articles